Amrutanjan Health Care Q2 FY26 results: PAT up 36% in H1, Re.1 interim dividend
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amrutanjan Health Care Q2 FY26: revenue Rs 117.70 cr, up 7% YoY; PAT Rs 13.96 cr, up 18% YoY. H1 revenue Rs 211.75 cr vs Rs 193.65 cr; H1 PAT Rs 22.27 cr vs Rs 16.41 cr, up about 36% YoY. Quarter EPS Rs 4.83 vs Rs 4.08. Board declared first interim dividend of Re.1 per share for FY26. OTC Products led growth; Beverages losses narrowed. Auditor issued an unmodified limited review report.
H1 PAT growth of 36% and an interim dividend of Re.1 per share signal strong performance and steady shareholder returns.